AMRN
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Amarin Corporation PLC (AMRN) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Growth (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C+ (2.7) | F (0.7) | C (2.5) | C (2.4) | C- (1.9) | C- (2.0) |
| 2026-08-04 | C+ (2.7) | F (0.7) | C (2.5) | C (2.4) | C- (1.9) | C- (2.0) |
| 2026-08-03 | C+ (2.7) | D+ (1.8) | C+ (2.8) | C (2.4) | C- (2.0) | C (2.3) |
| 2026-08-02 | C+ (2.7) | D+ (1.8) | C+ (2.8) | C (2.4) | C- (1.9) | C (2.3) |
| 2026-07-29 | C (2.4) | A+ (4.7) | B- (3.1) | D+ (1.7) | D+ (1.5) | C+ (2.7) |